Skip to content
PubMed This is a summary of 15 peer-reviewed journal articles Updated
Oncology · Pancreatic Neuroendocrine Tumor

Symptoms & Subtypes: Functional vs. Non-Functional pNETs

At a Glance

Pancreatic neuroendocrine tumors (pNETs) are classified as functional if they overproduce hormones that cause specific symptoms, or non-functional if they do not. Non-functional pNETs are more common and usually only cause symptoms like abdominal pain or jaundice when they grow large.

When you are diagnosed with a [pancreatic neuroendocrine tumor (-1 “Understanding Your pNET Diagnosis”), one of the first things your medical team will determine is whether the tumor is functional or non-functional. This classification is based entirely on whether the tumor cells are overproducing hormones that cause specific symptoms in your body [1][2].

Functional vs. Non-Functional: The Key Difference

The “neuroendocrine” cells that make up these tumors are naturally designed to produce hormones. In a functional pNET, the tumor cells are “active” and pump out large amounts of a specific hormone, such as insulin or gastrin, into your bloodstream [1]. These excess hormones cause distinct “syndromes” or sets of symptoms that often lead to a diagnosis [3].

In contrast, a non-functional pNET (NF-pNET) either does not produce hormones at all or produces them in such small amounts that they don’t cause a noticeable syndrome [1]. These are actually the most common type, representing 50% to 91% of all cases [4][5]. Because they don’t cause hormonal symptoms, they are often discovered “incidentally”—meaning they are found by accident on a scan for something else, like a kidney stone or an injury [6].

Specific Functional Subtypes

If your tumor is functional, it is named after the specific hormone it produces. Each has its own unique “calling card” of symptoms:

  • Insulinoma (Insulin): The most common functional pNET [7]. It overproduces insulin, causing hypoglycemia (dangerously low blood sugar). Patients often experience the Whipple Triad: symptoms like shakiness, confusion, or sweating; a documented low blood sugar level; and immediate relief after eating sugar [8][9].
  • Gastrinoma (Gastrin): Produces excess gastrin, leading to Zollinger-Ellison Syndrome. This causes the stomach to make too much acid, resulting in severe, painful stomach ulcers and chronic diarrhea [10][11].
  • Glucagonoma (Glucagon): Produces glucagon, often leading to the “4Ds” syndrome: Diabetes (high blood sugar), Dermatitis (a painful, migrating red rash called NME), Deep vein thrombosis (blood clots), and Depression or weight loss [12].
  • VIPoma (Vasoactive Intestinal Peptide): Produces VIP, which leads to WDHA syndrome: Watery Diarrhea, Hypokalemia (low potassium), and Achlorhydria (low stomach acid) [11].
  • Somatostatinoma (Somatostatin): An extremely rare tumor that produces somatostatin, which can cause a “shutdown” of digestive processes, leading to diabetes, gallstones, and oily stools (steatorrhea) [13].

Symptoms of Non-Functional Tumors

Because non-functional tumors don’t send out hormone signals, they are usually silent until they grow large enough to press on nearby organs. This is known as mass-effect [1][14]. Symptoms of mass-effect depend on where the tumor is located:

  • Jaundice: If a tumor in the “head” of the pancreas presses on the bile duct, it can cause yellowing of the skin and eyes [14].
  • Abdominal Pain: A large tumor can cause a deep, dull ache in the belly or back [14].
  • Bowel Obstruction: If the tumor presses on the stomach or intestines, it can cause nausea, vomiting, or a feeling of being full very quickly [14].

Whether your tumor is functional or non-functional, the goal of your care team is the same: to use the best treatment options to manage the tumor itself while ensuring any symptoms—whether from hormones or mass-effect—are carefully controlled [15].

Common questions in this guide

What is the difference between a functional and non-functional pNET?
A functional pancreatic neuroendocrine tumor overproduces specific hormones that cause distinct physical symptoms, such as dangerously low blood sugar or severe stomach ulcers. A non-functional pNET does not produce extra hormones and typically only causes symptoms when it grows large enough to press on nearby organs.
How do doctors test for a functional pNET?
Your medical team will look at your specific symptoms and may order targeted blood tests to measure your hormone levels. Depending on the symptoms you are experiencing, they might check your fasting insulin, gastrin, or glucagon levels to confirm a functional subtype.
What are the symptoms of a non-functional pNET?
Because they don't release excess hormones, non-functional pNETs are often silent until they grow large enough to cause a 'mass effect.' When this happens, they can cause symptoms by pressing on nearby organs, leading to deep abdominal pain, jaundice, or bowel obstruction.
What is an insulinoma and what symptoms does it cause?
An insulinoma is the most common type of functional pNET and it produces too much insulin. This leads to episodes of dangerously low blood sugar, causing symptoms like shakiness, sweating, and confusion that usually improve immediately after eating sugar.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my lab results and symptoms, is my tumor functional or non-functional?
  2. 2.If my tumor is functional, which specific hormone is it overproducing and what are the risks of that excess?
  3. 3.Do I need specific blood tests, such as fasting insulin, gastrin, or glucagon levels, to confirm the subtype?
  4. 4.For a non-functional tumor, is the size and location causing any compression on nearby organs (mass effect)?
  5. 5.How does the functional status of my tumor change our immediate treatment priorities—are we treating symptoms first or the tumor itself?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (15)
  1. 1

    Animal models of spontaneous pancreatic neuroendocrine tumors.

    Yu R

    Molecular and cellular endocrinology 2016; (421()):60-7.

    PMID: 26261055
  2. 2

    Diagnosis and Management of Functional Pancreatic Neuroendocrine Tumors in Children-A Systematic Review.

    Keretić D, Bašković M

    Diagnostics (Basel, Switzerland) 2025; (15(17)) doi:10.3390/diagnostics15172176.

    PMID: 40941664
  3. 3

    ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

    Falconi M, Eriksson B, Kaltsas G, et al.

    Neuroendocrinology 2016; (103(2)):153-71 doi:10.1159/000443171.

    PMID: 26742109
  4. 4

    Pancreatic neuroendocrine tumors.

    Varas Lorenzo M, Cugat Andorra E, Capdevila Castillón J

    Revista espanola de enfermedades digestivas 2017; (109(6)):480-481 doi:10.17235/reed.2017.4725/2016.

    PMID: 28253729
  5. 5

    Islet Cell Tumors of the Pancreas.

    Amin S, Kim MK

    Gastroenterology clinics of North America 2016; (45(1)):83-100.

    PMID: 26895682
  6. 6

    Surgery or active surveillance for pNETs < 2 cm: Preliminary results from a single center Brazilian cohort.

    Arra DASM, Ribeiro HSC, Henklain G, et al.

    Journal of surgical oncology 2022; (126(1)):168-174 doi:10.1002/jso.26931.

    PMID: 35689580
  7. 7

    An observational analysis of insulinoma from a single institution.

    Shao S, Zeng Z, Hu S

    QJM : monthly journal of the Association of Physicians 2018; (111(4)):237-241 doi:10.1093/qjmed/hcy006.

    PMID: 29319794
  8. 8

    Technical aspects of paediatric robotic pancreatic enucleation based on a case of an insulinoma.

    Schulte Am Esch J, Krüger M, Barthlen W, et al.

    The international journal of medical robotics + computer assisted surgery : MRCAS 2021; (17(6)):e2317 doi:10.1002/rcs.2317.

    PMID: 34297475
  9. 9

    Ectopic insulinoma: case report.

    Sun M, Luo Y, You Y, et al.

    BMC surgery 2019; (19(1)):197 doi:10.1186/s12893-019-0661-y.

    PMID: 31852474
  10. 10

    Current Medical Controversies in Zollinger-Ellison Syndrome.

    Jensen RT, Ramos-Alvarez I, Norton JA

    Biomedicines 2025; (13(12)) doi:10.3390/biomedicines13123051.

    PMID: 41463062
  11. 11

    Clinical treatment of gastrinoma: A case report and review of the literature.

    Zhang WD, Liu DR, Wang P, et al.

    Oncology letters 2016; (11(5)):3433-3437 doi:10.3892/ol.2016.4397.

    PMID: 27123130
  12. 12

    Glucagonoma and the glucagonoma syndrome.

    Song X, Zheng S, Yang G, et al.

    Oncology letters 2018; (15(3)):2749-2755 doi:10.3892/ol.2017.7703.

    PMID: 29435000
  13. 13

    Characteristics, therapy, and outcome of rare functioning pancreatic neuroendocrine neoplasms.

    Albers MB, Sevcik M, Wiese D, et al.

    Scientific reports 2024; (14(1)):18507 doi:10.1038/s41598-024-68290-1.

    PMID: 39122816
  14. 14

    Advanced metastatic pancreatic neuroendocrine tumor treated successfully with peptide receptor radionuclide therapy: a case report.

    Kumar A, Tanwar S, Gupta S, et al.

    Exploration of targeted anti-tumor therapy 2022; (3(3)):392-397 doi:10.37349/etat.2022.00089.

    PMID: 36045912
  15. 15

    The impact of failure to achieve symptom control after resection of functional neuroendocrine tumors: An 8-institution study from the US Neuroendocrine Tumor Study Group.

    Zaidi MY, Lopez-Aguiar AG, Poultsides GA, et al.

    Journal of surgical oncology 2019; (119(1)):5-11 doi:10.1002/jso.25306.

    PMID: 30481383

This page provides educational information about functional and non-functional pancreatic neuroendocrine tumors. It does not replace professional medical advice, and you should always consult your oncologist regarding your specific diagnosis and symptoms.

Get notified when new evidence is published on Neuroendocrine tumor of pancreas.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.